Albendazole Tablet

Albendazole is used for several helminth infections, but the appropriate regimen varies substantially by organism and clinical situation.

• Soil-transmitted helminths: WHO identifies albendazole as a recommended treatment for ascariasis, trichuriasis and hookworm infections.

• Neurocysticercosis: The U.S. ALBENZA label covers parenchymal infection caused by larval Taenia solium.

• Cystic hydatid disease: U.S. labeling includes hydatid disease involving the liver, lung and peritoneum caused by Echinococcus granulosus.

• Other worm infections: Albendazole is also used clinically for selected other helminth infections depending on local guidelines and specialist assessment.

Albendazole should not be assumed to treat every parasitic infection. WHO specifically notes that Strongyloides stercoralis is not sensitive to albendazole.

Albendazole dosing depends on the parasite and indication rather than simply the tablet strength. For WHO soil-transmitted helminth preventive-treatment programs, 400 mg as a single oral dose is a standard regimen for appropriate populations. This public-health regimen should not be automatically applied to every individual infection.

For the U.S.-labeled indications, ALBENZA dosing is different: adults and patients weighing 60 kg or more generally receive 400 mg twice daily for neurocysticercosis or hydatid disease, while lower-weight patients use weight-based dosing with a maximum of 800 mg/day. Treatment duration also differs by condition.

The correct regimen should therefore be selected by a clinician based on diagnosis, age, weight, infection severity, liver function and local treatment guidance.

Albendazole belongs to the benzimidazole anthelmintic class. It interferes with essential processes that parasites need to maintain their cellular structure and obtain energy, ultimately impairing their survival.

Feature	Practical meaning
Drug class	Benzimidazole anthelmintic
Target	Parasite cellular processes, including microtubule-related functions
Result	Impaired nutrient utilization and parasite survival
Human effect	Helps eliminate susceptible helminth infections when the correct regimen is used

The active systemic metabolite, albendazole sulfoxide, contributes substantially to the treatment of infections requiring systemic exposure.

Follow the prescription or product instructions for the specific infection.

• Take the medicine at the prescribed dose and duration; do not repeat doses simply because symptoms continue.

• For ALBENZA's labeled neurocysticercosis and hydatid-disease regimens, tablets are taken with food.

• Some albendazole regimens are short single-dose treatments, while systemic infections can require repeated treatment cycles.

• Do not substitute a 200 mg tablet for a 400 mg tablet without following the prescribed regimen.

• If treatment is prolonged, laboratory monitoring may be required.

The FDA label recommends blood-count and liver-enzyme monitoring during prolonged ALBENZA therapy, particularly at the beginning of treatment cycles and at specified intervals.

Short courses are often tolerated well, but adverse effects can occur.

Possible effects include:

• Abdominal discomfort or nausea

• Vomiting or dizziness

• Headache

• Temporary increases in liver enzymes

• Loss of appetite

More serious problems are possible with prolonged or intensive treatment, including liver injury and reductions in blood-cell counts. The prescribing information therefore recommends appropriate laboratory monitoring during prolonged therapy.

Tell the prescriber about other medicines. Cimetidine, dexamethasone and praziquantel can affect albendazole-sulfoxide exposure, and corticosteroids or anticonvulsants may be used alongside albendazole in selected neurocysticercosis cases.

Albendazole requires particular caution when treatment is prolonged or when higher systemic exposure is required. Liver injury and reductions in blood-cell counts can occur, so liver-function tests and blood counts may be required during extended treatment. Patients with existing liver disease should tell their healthcare professional before treatment.

Pregnancy requires special consideration. The U.S. prescribing information recommends pregnancy testing before therapy in women of reproductive potential and advises contraception during treatment and for the specified period afterward. The appropriate pregnancy precautions can vary with the indication and local guidance.

Seek medical advice promptly for yellowing of the skin or eyes, dark urine, unusual bruising or bleeding, persistent fever, severe weakness, or symptoms suggesting a serious allergic reaction.

Albendazole is not a universal “dewormer” for every parasite. The diagnosis matters, and Strongyloides infection in particular requires a different approach because WHO notes that it is not sensitive to albendazole. Children, pregnant or breastfeeding individuals, and people with liver disease should receive condition-specific professional advice before treatment.

This information is for general education and does not replace advice from a doctor, pharmacist or qualified healthcare professional.